The model demonstrates that in hypercholesterolemia subjects, a 50% decrease of LDL-C by inclisiran is achieved with a 10% lesser reduction in PCSK9, which could not be explained by differences in baseline levels alone. Here, PCSK9 is linked to familial hypercholesterolemia.